Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novartis MenB Vaccine in Immunocompromised Children
NCT02141516Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2014
- Primary completion
- Mar 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
A Phase 3 trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal disease, sponsored by Novartis. Started May 2014; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT02141516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141516.